Intas Pharma launches first etanercept biosimilar
Intas Pharmaceuticals has launched INTACEPT, the first biosimilar to Amgen’s Enbrel (etanercept). INTACEPT has been launched in two strengths, 25mg in 0.5... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
INTACEPT
Our Popular Courses
Recent Articles
- Stada acquired 15 OTC brands of GSK
- Case Study : Rx-to-OTC switch of Voltaren arthritis pain
- Analysis of Business Deal: Collegium Pharma acquired of U.S. Rights to Nucynta Franchise for $375M
- Cipla to acquire four women’s health brands from Wanbury
- Insight on Curis, Aurigene collaboration for development and commercialization of CA-170
- Nestlé, Valbiotis partners to develop & commercialize plant-derived active substance, TOTUM-63 to reduce risk of developing type 2 diabetes
- Strides to acquire 18 ANDAs from Pharmaceutics International
- CODA Biotherapeutics acquired 3 clinical stage assets from Attenua
- How biosimilar priced in US market?
- Pfizer launched Zirabev, Ruxience, Trazimera biosimilar in US
- Merck’s Dificid received USFDA approval for Infections in Children
- EyePoint Pharmaceuticals and Ocumension Therapeutics’s Exclusive License Agreement to Develop and Commercialize DEXYCU
- Helsinn out-licenses Akynzeo and Onicit in Russia to Berlin-Chemie
- Insight on 2019 USFDA New Drug Approval
- Insight on J&J’s TB mass awareness campaign in India
- CUTX-101 of Fortress Biotech gets US FDA rare pediatric disease designation to treat Menkes disease
- What is Edible security tag?
- Acquisition in Pharma: Why Astellas to acquire Xyphos Biosciences?
- US FDA issued CRL to ViiV Healthcare for use of cabotegravir and rilpivirine long-acting regimen for treatment of HIV
- US FDA issues Complete Response Lette to Takeda’s Entyvio for maintenance therapy in adults with ulcerative colitis